| Serial Number | 98081098 |
| Word Mark | T-CEPTOR |
| Filing Date | Wednesday, July 12, 2023 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, December 24, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 24, 2024 |
| Goods and Services | Pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; chemical and biological pharmaceutical preparations for medical purposes, namely, for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; chemical preparations for use in DNA analysis for medical purposes; DNA synthesis inhibitors for medical purposes, namely, pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; biological preparations for the treatment of cancer; biological preparations for the treatment of viral and bacterial infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use for the treatment of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; immunotherapeutic drugs namely, pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; reagents for medical use; diagnostic preparations for medical use; diagnostic reagents for medical use; preparations for detecting genetic predispositions for medical purposes |
| Goods and Services | Medical services; diagnostic and prognostic medical services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health care services relating to DNA, genetics, and genetic pathogen testing for diagnostic or treatment purposes; medical screening and assaying in the nature of medical laboratory analysis services relating to the treatment of persons; DNA screening for medical purposes |
| Goods and Services | Scientific and technological services, namely, scientific research and development in the field of pharmaceuticals for genome engineering and biopharmaceutical drug development for protection from infections, cancer, disease or inflammation; technical research in the field of pharmaceutical studies; industrial analysis and industrial research services in the field of pharmaceuticals and genome engineering; research in the field of DNA repair technology; design and development of computer hardware and software; genetic microbiology and microbiome research for scientific research purposes; scientific research in the field of genetics and genetic engineering; clinical research in the field of pharmaceuticals, biopharmaceutical drug development and genome engineering for protection and prevention from infections, cancer, disease or inflammation; scientific research in the nature of conducting clinical trials for others; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibiotics; research and development of microorganisms and cells in the nature of guided nuclease-based biocides; scientific research in the nature of conducting clinical trials for pharmaceutical products for others; bacteriological research; scientific research for medical purposes in the field of viruses and viral diseases; biological research; scientific screening and assaying being drug screening for scientific research purposes; chemical analysis; chemical research; DNA screening for scientific research purposes; genetic testing of laboratory animals for research purposes; biochemical engineering services being biochemical research and development; providing medical and scientific research information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific research information in the field of pharmaceuticals and scientific research consulting in the field of pharmaceuticals |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 10, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 10, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 10, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | T-Therapeutics Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Cambridge CB216AL GB |
| Party Name | T-Therapeutics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Cambridge CB216AL GB |
| Event Date | Event Description |
| Saturday, July 15, 2023 | NEW APPLICATION ENTERED |
| Thursday, August 10, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, March 20, 2024 | ASSIGNED TO EXAMINER |
| Saturday, March 23, 2024 | NON-FINAL ACTION WRITTEN |
| Saturday, March 23, 2024 | NON-FINAL ACTION E-MAILED |
| Saturday, March 23, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, March 27, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, March 27, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, March 27, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Friday, May 31, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, May 31, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, May 31, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, June 11, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, June 11, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, June 11, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, July 10, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, July 10, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, July 10, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, October 9, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, October 9, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, October 9, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, November 13, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, November 13, 2024 | FINAL REFUSAL E-MAILED |
| Wednesday, November 13, 2024 | FINAL REFUSAL WRITTEN |
| Friday, November 22, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Friday, November 22, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, November 22, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, November 22, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, November 26, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, December 18, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, December 24, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, December 24, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |